Home / The Science

The Science

A potent, consistent, ready-to-use therapy.

CuraCell's first-in-class allogeneic stem-cell therapy is built to treat the cause — off-the-shelf, fast-acting and gentle. Mesenchymal stem cells calm chronic inflammation and actively drive tissue repair.

The problem

Chronic conditions deserve more than symptom control.

For arthritis, kidney disease and chronic inflammation, today's options often manage the symptoms while the underlying damage keeps progressing.

An elderly owner walking a senior dog living with a chronic condition

Medication only masks it

Painkillers wear off

Anti-inflammatories and painkillers ease symptoms for a while — but carry long-term organ and toxicity risks, and never repair the underlying damage.

Surgery is hard on pets

Invasive & costly

Joint and structural procedures are expensive and hard on pets, with long, painful recoveries for animal and owner alike.

A real treatment gap

Few options repair

Few safe, scalable options actually repair tissue and calm chronic inflammation at the source — so conditions keep progressing.

The solution

Four reasons it's different.

Donor-derived, minimally invasive, regenerative, and safe — proven across 500+ documented treatments.

Off-the-shelf

Donor-derived cells, ready the moment your pet needs them — no painful harvesting from the patient.

Minimally invasive

A simple injection means far less stress for your pet, and a faster recovery than surgery.

Regenerative power

Mesenchymal stem cells calm chronic inflammation and actively drive tissue repair at the source.

Safety first

Minimal rejection risk and no known long-term toxicity across 500+ documented treatments to date.

A scientist holding a vial of activated CuraCell stem cells in the lab

How it works

Proprietary activation, standardized doses.

Our proprietary cytokine programming primes the cells for potency — delivering a consistent, off-the-shelf therapeutic dose in four simple steps.

Donor cells

A high-quality allogeneic (donor-derived) source — no harvesting from your pet.

Activation

Proprietary cytokine programming primes the cells for potency and consistency.

Standardized dose

Manufactured to a consistent, off-the-shelf therapeutic dose.

Treatment

Delivered as a quick, minimally invasive injection at the clinic.

A scientist checking cell samples at cryogenic cell-banking tanks in the CuraCell lab

The technology

Programmed cells, repeatable results.

Unlike autologous approaches that harvest and culture a single patient's own cells, CuraCell uses donor-derived mesenchymal stem cells that are activated with natural cytokines — priming them for immune-modulation and tissue repair before they ever reach your pet.

Because every batch is manufactured to a standardized therapeutic dose, your vet delivers the same potent, quality-controlled treatment every time — no waiting weeks for cells to grow.

Proprietary process

Exclusive activation, production and cryo-preservation methods refined over a decade of research.

Strict QC

Reproducible, academically-backed manufacturing for consistent outcomes.

Mechanism of action

How stem cells actually heal.

Mesenchymal stem cells (MSCs) — often called "medicinal signaling cells" — don't simply replace damaged tissue. They actively orchestrate the body's own repair through four coordinated biological mechanisms.

Immunomodulation

MSCs reprogram immune cells — macrophages, T-cells and dendritic cells — shifting them from a pro-inflammatory to a pro-healing state.

Paracrine secretome

They release a rich secretome of cytokines, growth factors and exosomes that signal surrounding cells to repair and regenerate.

Anti-inflammatory

By secreting mediators such as IL-10 and PGE2, MSCs suppress pro-inflammatory signals like TNF-α and IL-6 — calming chronic inflammation at the source.

Tissue regeneration

They stimulate resident progenitor cells, promote new blood-vessel growth (angiogenesis) and reduce scarring — rebuilding healthy tissue.

Mechanisms summarised from the peer-reviewed literature on MSC paracrine activity and immunomodulation — see Wang et al., Nature Immunology 2014; Ren et al., Cell Stem Cell 2008; and reviews in Frontiers in Veterinary Science (2020).

Why allogeneic

Off-the-shelf beats per-patient.

Most veterinary stem-cell therapy is autologous — harvested from the patient, then cultured for weeks. CuraCell's allogeneic donor-derived model is ready immediately, manufactured to a consistent standard, and free of donor-to-donor variability.

	CuraCell · Allogeneic	Autologous (per-patient)	Pharmaceuticals	Surgery
Availability	Off-the-shelf, immediate	Weeks of culture per patient	In stock	Scheduled procedure
Mode of action	Regenerative · root-cause	Regenerative	Symptomatic only	Structural only
Invasiveness	Simple injection	Harvest + inject	Oral / injection	Invasive surgery
Consistency	Standardized dose, strict QC	Varies by patient	Standardized	Varies by case
Scalability	Mass-produced	One patient at a time	Mass-produced	Per case
Market reach (Asia)	8 markets	Local / per-clinic	Broad	Local

Market position

Built for 8 Asian markets.

CuraCell's proprietary activation, production and cryo-preservation methods power an off-the-shelf therapy ready to scale across the fastest-growing pet-health region in the world.

$10B+

Annual unmet need

Global spend on pet chronic disease each year.

80%

Inadequately treated

Of cats & dogs with chronic conditions receive insufficient care.

The result

A highly potent, standardized off-the-shelf therapy.

Every dose is activated and manufactured to the same exacting standard — so your vet can deliver consistent, repeatable results, ready the moment your pet needs them.

See what we treat →

A cluster of activated CuraCell stem cells